The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study-Reference-Cited by-同舟云学术

The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study

Published:2024-04-28 Issue:7 Volume:29 Page:994-1001
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Sato Sho,Ssuzuki Takashi,Chinen Takashi,Yamaguchi Hironori,Suzuki Yusuke,Hokamura Nobukazu,Saze Zenichiro,Kono Koji,Takahashi Keita,Yano Fumiaki,Kunisaki Chikara,Kosaka Takashi,Endo Itaru,Ichikawa Yasushi,Miyawaki Yutaka,Sato Hiroshi,Shimada Hideaki^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02532-0.pdf

Reference23 articles.

1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249

2. Lee SJ, Kim S, Kim M et al (2015) Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study. BMC Cancer 14(15):693

3. Bleiberg H, Conroy T, Paillot B et al (1997) Randomised Phase II Study of Cisplatin and 5Fluorouracil (5FU) Versus Cisplatin Alone in Advanced Squamous Cell Oesophageal Cancer. Europ J Cancer 33:1216–1220

4. Sun JM, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 28(398):759–771

5. Doki Y, Ajani JA, Kato K et al (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449–462

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases;Journal of Gastroenterology;2024-08-17

2. Can Immune Checkpoint Inhibitors Pave the New Way for “Conversion Surgery” in Unresectable Esophageal Cancer?;Annals of Surgical Oncology;2024-06-10